← All stocks

Bristol Myers Squibb Co

BMYPharmaceuticalsLatest filing used: 2026-10-29Filings on SEC EDGAR ↗

On sale Dividend grower High cash margin

Fair value per share

$67.67

from SEC filings only

Last close

$63.42

Nov 13, 2026

6.3% below fair value

Margin of safety price
$50.75
25% below fair value
Stress case
$54.68
if things go badly

Its filings point to about $67.67 a share, most likely between $49.76 and $88.26.

Where it sits

82 of the 653 stocks we value that have a close are further below their estimates.

Counts the 653 stocks that have both a value and a close as of Nov 13. Positions are squeezed so the biggest gaps fit.

The short case

In favour

  • Its last close is about 6% below what its filings say it is worth.
  • It turns about 30% of its sales into cash in a typical year.
  • It has raised its dividend over the last five years.

Against

  • It carries more debt than equity.

Written automatically from the filings, by the same rules for every company. Not a recommendation.

Price tags

The last close next to our fair value, the filings-based estimate above. Profit and cash flow: the 12 months to September 30, 2026.

MeasureAt last close$63.42Nov 13At our fair value$67.67
Market valueAll 2.1 billion shares at that price (the diluted count, which includes stock options and awards)$130.2B$138.9B
Price / earnings (P/E)Dollars paid for each $1 of yearly profit14.1×15.0×
Price / free cash flowDollars paid for each $1 of cash left each year after paying for equipment14.0×15.0×
EV / EBITDAPrice of the whole business (shares plus debt, less cash) for each $1 of yearly profit before interest, tax and wear and tearNot shown: we couldn't find every number this needs in the filings.Not shown: we couldn't find every number this needs in the filings.

Our own arithmetic on the filings, the last close and our fair value, which is an estimate. One unusual year can push any of these very high or very low. How we work these out

Five areas

15 of 25 checks passedStrong in 2 of 5 areas

GrowthWeak · 2 of 5
  • Revenue up 5%+ a year over 3 years (not passed)
  • Revenue up 5%+ a year over 5 years (not passed)
  • Earnings per share up 5%+ a year over 5 years (no data)
  • Revenue up over the last 12 months (passed)
  • Earnings per share up over the last 12 months (passed)
ProfitabilityWeak · 1 of 5
  • Return on equity of 15%+ (last 12 months) (passed)
  • Return on equity of 12%+ (5-year average) (not passed)
  • Return on invested capital of 10%+ (5-year average) (not passed)
  • Operating margin of 10%+ (5-year average) (no data)
  • Operating margin holding up (last 12 months vs 5 years) (no data)
Cash generationStrong · 5 of 5
  • Cash earnings positive in almost every year (at most one bad year) (passed)
  • Typical year turns 10%+ of revenue into cash (passed)
  • Latest year at or above the typical year (passed)
  • Free cash flow positive (last 12 months) (passed)
  • Revenue larger than 5 years ago (passed)
Balance sheetWeak · 2 of 5
  • Debt no larger than equity (not passed)
  • Cash and short-term investments exceed debt (not passed)
  • Positive shareholders' equity (passed)
  • Debt clearly tagged in the filings (passed)
  • Operating margin above zero (last 12 months) (no data)
Shareholder returnsStrong · 5 of 5
  • Pays a dividend (passed)
  • Dividend paid in each of the last 5 years (passed)
  • Dividend grew over 5 years (passed)
  • Pays out 75% or less of earnings (passed)
  • Share count flat or falling over 5 years (passed)

Flags

No flags raised in the latest filing.

How we got this number

In a typical year BMY kept 30% of its revenue as cash after running and maintaining the business (before interest). We assume revenue shrinks 0.2% a year for five years, then recovers to 2.5% growth by year ten, and discount the cash at 9.0% a year (the 10-year Treasury yield plus 5 points, blended with the cost of its debt). That is worth $67.67 a share today.

Technical details
Model
Discounted cash flow on cash earnings
Cash-earnings margin: typical year (worst / best 3-year stretch)
30.4% (28.6% / 30.7%)
Years used
2021–2025
Revenue growth, years 1–5 (range tested)
-0.2% (-5 to 5%)
Capital needed per $1 of new revenue
$0.15 equipment, $0.12 working capital
Discount rate
9.0%
Revenue base
$48.2B (lower of TTM and last FY)
Debt / cash
$43.6B / $12.6B
Value if investors require Treasury + 3 / + 8 points (we use + 5)
$83.68 / $52.78
If growth after year 10 keeps today's returns
$80.77
Likely range
10th–90th percentile of 4,000 runs with different assumptions
Required return
10-year Treasury 5.15% (2026-11-13) + 5%

What the price assumes

For our model to reach the last close of $63.42 (Nov 13, 2026), BMY would have to keep 29¢ of every $1 of sales as cash. In a typical year it kept 30¢.

What the price needs
29¢
Its typical year
30¢
Its last 3 years
30¢
Its best year
34¢
Its worst year
27¢

In our model, a typical year's margin would already cover the last close.

Typical, best and worst years are from the 5 years we checked in its filings (2021–2025). Everything else stays as described above, including the growth path and the discount rate.

Technical details

Value per share is a straight line in the margin until it reaches zero: value = margin × cash factor − (growth spending + debt and other claims) per share. We solve for the margin that gives the last close, with growth, discount rate, equipment and working capital held as in the main model.

Revenue base $48.2B. Growth −0.2% for five years, fading to 2.5% by year 10. Discount rate 9.0%. At 30.4¢ the filings-based value is $67.67. Each extra 1¢ of margin adds $2.73 a share. The last close is $63.42, which is $4.24 below the filings-based value, so the margin would have to fall by 1.6¢, to 28.9¢.

Terminal rule: Growth after year 10 earns only the discount rate, so it adds no value.

Ten years of results

Revenue

$48.2B in FY2025, down 0% on the year before

FY2016: $19.4BFY2017: $20.8BFY2018: $22.6BFY2019: $26.1BFY2020: $42.5BFY2021: $46.4BFY2022: $46.2BFY2023: $45.0BFY2024: $48.3BFY2025: $48.2B$25B$50BFY16FY19FY22FY25$48.2B
Show as table
YearRevenue
FY2016$19.4B
FY2017$20.8B
FY2018$22.6B
FY2019$26.1B
FY2020$42.5B
FY2021$46.4B
FY2022$46.2B
FY2023$45.0B
FY2024$48.3B
FY2025$48.2B

Cash earnings as a share of sales

30.5% of sales in FY2025

FY2021: 33.7%FY2022: 27.4%FY2023: 30.4%FY2024: 28.0%FY2025: 30.5%0%20%40%FY16FY19FY22FY2531%
Show as table
YearCash earnings as a share of sales
FY2016–
FY2017–
FY2018–
FY2019–
FY2020–
FY202133.7%
FY202227.4%
FY202330.4%
FY202428.0%
FY202530.5%

Dividends per share

$2.49 a share in FY2025

FY2016: $1.53FY2017: $1.57FY2018: $1.61FY2019: $1.68FY2020: $1.84FY2021: $2.01FY2022: $2.19FY2023: $2.31FY2024: $2.42FY2025: $2.49$1.25$2.5FY16FY19FY22FY25$2.49
Show as table
YearDividends per share
FY2016$1.53
FY2017$1.57
FY2018$1.61
FY2019$1.68
FY2020$1.84
FY2021$2.01
FY2022$2.19
FY2023$2.31
FY2024$2.42
FY2025$2.49

Shares outstanding

Share count rose 21% over 9 years

FY2016: 1.68BFY2017: 1.65BFY2018: 1.64BFY2019: 1.71BFY2020: 2.26BFY2021: 2.25BFY2022: 2.15BFY2023: 2.08BFY2024: 2.03BFY2025: 2.04B01.25B2.5BFY16FY19FY22FY252.04B
Show as table
YearShares outstanding
FY20161.68B
FY20171.65B
FY20181.64B
FY20191.71B
FY20202.26B
FY20212.25B
FY20222.15B
FY20232.08B
FY20242.03B
FY20252.04B

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-10-29. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13. Price tags: our own arithmetic on the SEC figures, the last close and our fair value.